Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial

Annals of Oncology

Volumn 10, Issue 11, 1999, Pages 1307-1310

  Fields Jones, S ^a   Koletsky, A ^b   Wilding, G ^c   O'Rourke, M ^d   O'Rourke, T ^a   Eckardt, J ^a   Yates, B ^e   McGuirt, C ^e   Burris III, H A ^a,f  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b JFK Comprehensive Cancer Center   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Hematol and Oncology Associates PA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Clinical benefit; Prostate cancer; Vinorelbine

Indexed keywords

NAVELBINE; ONDANSETRON; PREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HORMONE RESISTANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HORMONES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0032787177     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008315106697     Document Type: Article

References (11)

1. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996; 88: 779-81.
2. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-13.
3. Fields S, Burris H, Wilding G et al. Evaluating the role of Navelbine in hormone-refractory prostate cancer (HRPC): A clinical benefit model. Proc Am Soc Clin Oncol 1994; 13: 727 (Abstr).
4. Houde RW. Methods for measuring clinical pain in humans. Acta Anaesthesiol Scand 1982; 74 (Suppl): 25-9.
5. Moore MJ, Osoba D, Murphy K et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994; 12: 689-94.
6. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
7. Hudes GR, Greenberg R, Krigel RL et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 1992; 10: 1754-61.
8. Pienta KJ, Redman B, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12.
9. Kelly WK, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607-15.
10. Maulard-Durdux C, Dufour B, Hennequin C et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77: 1144-8.
11. Reese D, Burris H, Belledgrun A et al. A phase I-II study of Navelbine (vinorelbine) and estramusline in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1996; 15: 259 (Abstr).